Shares of Metlife Inc (NYSE:MET) have been given a consensus recommendation of “Hold” by the sixteen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $55.08.

Several analysts recently issued reports on the company. Zacks Investment Research raised Metlife from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Friday, October 5th. Wells Fargo & Co reissued a “buy” rating and set a $60.00 target price on shares of Metlife in a research note on Thursday, September 27th. Morgan Stanley decreased their target price on Metlife from $53.00 to $52.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 11th. Sandler O’Neill reissued a “hold” rating and set a $50.00 target price on shares of Metlife in a research note on Thursday, August 2nd. Finally, B. Riley decreased their target price on Metlife from $58.00 to $50.00 and set a “neutral” rating on the stock in a research note on Monday, July 16th.

Shares of NYSE MET traded up $0.22 during trading on Friday, hitting $43.84. The company had a trading volume of 6,045,200 shares, compared to its average volume of 5,966,901. The company has a quick ratio of 0.15, a current ratio of 0.15 and a debt-to-equity ratio of 0.29. Metlife has a 12 month low of $42.80 and a 12 month high of $55.91. The company has a market capitalization of $44.43 billion, a P/E ratio of 9.73, a price-to-earnings-growth ratio of 0.68 and a beta of 1.23.

Metlife (NYSE:MET) last posted its quarterly earnings data on Wednesday, August 1st. The financial services provider reported $1.30 EPS for the quarter, topping the consensus estimate of $1.17 by $0.13. Metlife had a return on equity of 9.17% and a net margin of 6.12%. The firm had revenue of $21.22 billion for the quarter, compared to the consensus estimate of $15.65 billion. During the same quarter last year, the company earned $1.04 earnings per share. The business’s revenue for the quarter was up 36.8% compared to the same quarter last year. Research analysts anticipate that Metlife will post 5.21 EPS for the current year.

In other Metlife news, Chairman Steven A. Kandarian sold 42,805 shares of Metlife stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $47.03, for a total value of $2,013,119.15. Following the sale, the chairman now owns 559,097 shares of the company’s stock, valued at approximately $26,294,331.91. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Steven A. Kandarian sold 85,683 shares of Metlife stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $46.93, for a total value of $4,021,103.19. Following the completion of the sale, the chairman now directly owns 585,005 shares in the company, valued at approximately $27,454,284.65. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in MET. FMR LLC increased its stake in Metlife by 9.2% in the 2nd quarter. FMR LLC now owns 46,737,949 shares of the financial services provider’s stock worth $2,037,775,000 after acquiring an additional 3,921,155 shares during the last quarter. Pzena Investment Management LLC boosted its holdings in shares of Metlife by 39.3% in the 2nd quarter. Pzena Investment Management LLC now owns 8,314,788 shares of the financial services provider’s stock worth $362,525,000 after purchasing an additional 2,346,866 shares during the period. Morgan Stanley boosted its holdings in shares of Metlife by 12.3% in the 2nd quarter. Morgan Stanley now owns 6,357,267 shares of the financial services provider’s stock worth $277,177,000 after purchasing an additional 696,768 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Metlife by 200.8% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 920,727 shares of the financial services provider’s stock worth $40,146,000 after purchasing an additional 614,667 shares during the period. Finally, Royal London Asset Management Ltd. purchased a new position in shares of Metlife in the 2nd quarter worth approximately $21,849,000. 77.54% of the stock is currently owned by institutional investors and hedge funds.

About Metlife

MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.

Featured Article: How Investors Use a Balance Sheet

Analyst Recommendations for Metlife (NYSE:MET)

Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.